

DATE: January 9, 2003

SHEET 1 of 2

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4573.US.C6

SERIAL NO.

10/086,409

APPLICANT(S)

J.C. Hunt, et al.

FILING DATE

November 19, 2001

GROUP

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	4629783	12/16/1986	Cosand			
	A2	5156949	10/20/1992	Luciw, et al.			
	A3	4904581	02/27/1990	Burger, et al.			
	A4	4683136	07/1987	Milich, et al.			
	A5	4843011	06/27/1989	Sarnadharan, et. al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRAN- SLATION YES NO
	B1	0227169	07/01/1987	EP			
	B2	0219106	04/22/1987	EP			
	B3	87/02775	05/07/1987	WO			
	B4	0214709	09/29/1993	EP			
	B5	0248534	12/09/1987	EP			
	B6	0185444	06/25/1986	EP			
	B7	86/04336	07/31/1986	WO			
	B8	0201716	08/10/1994	EP			
	B9	0199301	10/29/1986	EP			
	B10	87/02988	05/27/1987	WO			
	B11	0199438	05/30/1990	EP			
	B12	0212532	03/04/1987	EP			
	B13	86/06414	11/06/1986	WO			
	B14	87/02775	05/07/1987	WO			

RECEIVED

JAN 14 2003

TECH CENTER 1800/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Curran, et al., "The Epidemiology of AIDS: current Status and Future Prospects," Science 229:1352-1357 (1985)
----	---

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4573.US.C6

SERIAL NO.

10/086,409

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)

J.C. Hunt, et al.

FILING DATE

November 19, 2001

GROUP

TECH CENTER 1600/2900

JAN 14 2003

RECEIVED



(37 CFR 1.98 (b))

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C2	Abbott Laboratories, Human Immunodeficiency Virus 1 Antigen (Env/Core) (Recombinant, e. coli)-EIA (product literature).
C3	Veronese, et al., "Characterization of gp41 As The Transmembrane Protein Coded by the HTLV-III/LAV Envelope Gene," Science, 229:1402-1405 (1985)
C4	Gosting, et al., "Monoclonal Antibodies to gp110 and gp41 of Human Immunodeficiency Virus," J. Clin. Micro 25:845-848 (1987)
C5	Zweig, et al., "Partial Purification of Native HIV Transmembrane Protein gp41: Generation of Polyclonal and Monoclonal Antibodies," AIDS 4:51-62 (1988)
C6	Papsidero, et al., "Monoclonal Antibody Identifies a Highly Conserved and Immunodominant Epitope of the Human Immunodeficiency Virus Transmembrane Protein," Hybridoma 7:117-128 (1988)
C7	Council on Scientific Affairs, "Status Report on the Acquired Immunodeficiency Syndrome," JAMA, 254:1342-1345 (1985)
C8	Fauci, et al., "The Acquired Immunodeficiency Syndrome: An Update," Ann. Int. Med. 102:800-813 (1985)
C9	Fauci, et al., "The Acquired Immunodeficiency Syndrome (AIDS): An Update," Int. Arch. Allergy Appl. Immun. 77:81-88 (1985)
C10	Dassey, et al., "AIDS and Testing for AIDS," JAMA, 255, 743-745 (1986)
C11	Chalmers et al., "The Impact of Routine HTLV-III Antibody Testing of Blood and Plasma Donors on Public Health," JAMA, 256, 1778-1783 (1986)
C12	Ratner, et al., "Complete Nucleotide Sequence of the AIDS virus, HTLV-III," Nature 313:277-283 (1985)
C13	Dawson, et al., "Reliable Detection of Individuals Seropositive for the Human Immunodeficiency Virus (HIV) by Competitive Immunosassays Using Escherichia coli-Expressed HIV Structural Proteins," J. Infect. Dis. 157:149-155 (Jan. 1988)
C14	Frosner, et al., "Diagnostic Significance of Quantitative Determination of HIV Antibody Specific for Envelope and Core Proteins," Lancet, I:159-160 (1987)
C15	Goudsmit, et al., "Concise Communications," J. Infect. Dis. 155:558-560 (1987)
C16	Habermehl, et al., "Specificity and Sensitivity of Anti-HTLV-III/LAV Determinations with a Recombinant Antigen Competitive ELISA," Infection 14:216 (1987)
C17	Dienhardt, et al., "Sensitivity and Specificity of Eight Commercial and One Recombinant Anti-HIV Elisa Tests," Lancet 3:40 (Jan. 1987)
C18	Denis, et al., "Efficacy of Five Enzyme Immunoassays for Antibody to HIV in Detecting Antibody to HTLV-IV," Lancet 7:324 (Feb. 1987)
C19	Allain, et al., "Serological Markers in Early Stages of Human Immunodeficiency Virus Infection in Haemophiliacs," Lancet 29:1233-1236 (Nov. 1986)
C20	Gallaher, et al., "A General Model for the Transmembrane Proteins of HIV and Other Retroviruses," AIDS Research and Human Retroviruses 5 (No.4):431-440 (1989)
C21	Banapour, et al., "Characterization and Epitope Mapping of a Human Monoclonal Antibody Reactive with the Envelope Glycoprotein of Human Immunodeficiency Virus," Journal of Immunology, 139 12:4027-4033 (December 15, 1997)
C22	M.A. Muesing, et al., "Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus," Nature, 313:450-458, (February 7, 1985)
C23	Kennedy, et al., "Antiserum To A Synthetic Peptide Recognizes The HTLV-III Envelope Glycoprotein," Science, 231:1556-1559 (March 28, 1986)
C24	Bangs, Ph.D., Uniform Latex Particles, Seragen Diagnostics, Inc. 1 <sup>st</sup> Edition, (Oct. 1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)



1642

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J.C. Hunt, et al.

Serial No.: 10/086,409

Filed: November 19, 2001

For: MOUSE MONOCLONAL ANTIBODY  
(5-21-3) TO HUMAN  
IMMUNODEFICIENCY VIRUS GP41  
PROTEIN

Attorney Docket No.: 4573.US.C6

Examiner: Not Yet Assigned

Group Art Unit: 1642

Certificate of Mailing under 37 CFR §1.8(a):  
I hereby certify that this paper (along with any  
paper referred to as being attached or  
enclosed) is being deposited with the United  
States Postal Service with sufficient postage as  
First Class Mail addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

Date of Deposit: January 9, 2003.

Kimberly A. Iorio

TRANSMITTAL LETTER

RECEIVED

JAN 14 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington D.C. 20231

Dear Sir:

Enclosed herewith for the patent application identified above entitled MOUSE MONOCLONAL ANTIBODY (5-21-3) TO HUMAN IMMUNODEFICIENCY VIRUS GP41 PROTEIN are the following:

1. Information Disclosure Statement (1 Page);
2. Form PTO 1449 (2 Pages), in duplicate;
3. References as cited on PTO 1449 (38 references, not including references previously submitted in U.S. Serial No. 08/856,155); and
4. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.



23492

ABBOTT LABORATORIES  
Telephone: (847) 938-3137  
Facsimile: (847) 938-2623

Respectfully submitted,  
J.C. Hunt, et al.

Dianne Casuto  
Registration No. 40,943  
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J.C. Hunt, et al.

Serial No.: 10/086,409

Filed: November 19, 2001

For: MOUSE MONOCLONAL ANTIBODY  
(5-21-3) TO HUMAN  
IMMUNODEFICIENCY VIRUS GP41  
PROTEIN

Attorney Docket No.: 4573.US.C6

Examiner: Not Yet Assigned

Group Art Unit: 1642


Certificate of Mailing under 37 CFR

§1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

Date of Deposit: January 9, 2003.

  
Kimberly A. Iorio

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Assistant Commissioner for Patents  
Washington, D.C. 20231

JAN 14 2003

Dear Sir:

TECH CENTER 1600/2800

The following information is submitted, pursuant to 37 CFR §§1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR §1.56. This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO 1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Copies of references are also enclosed except where previously submitted in U.S. Serial No. 08/856,155, filed May 14, 1997, from which this application claims priority.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR §1.97(b). Accordingly, no charge is required.



23492

ABBOTT LABORATORIES  
Telephone: (847) 938-3137  
Facsimile: (847) 938-2623

Respectfully submitted,  
J.C. Hunt, et al.



Dianne Casuto  
Registration No. 40,943  
Attorney for Applicants